Colour key								
	Minimum requirements as set out in Directive 2004/23/EC							
More stringent testing - legally binding on national level								
	More stringent testing - recommended on national level							
	Not legally binding and not recommended on national level							

#### Non-reproductive tissues and cells

Tested pathogen	Donor test/ technique	Legally binding	Recommended	Recommending	Circumstances for application			Regional differences	Further comments
			on national level	authority/ association	Donor profile	Tissue/cell type	Comments		
VIRAL									
HIV 1 and HIV 2	Anti-HIV 1	YES	NO	NO	all	all	no comments	NO	No plans for changes to the
	Anti-HIV 2	YES	NO	NO	all	all	no comments		legislation at the moment
	HIV 1p24								
	HIV NAT						as verification test		
	Other technique								
Hepatitis B	HBs Ag	YES	NO	NO	all	all	no comments	NO	No plans for changes to the
	Anti-HBc	YES	NO	NO	all	all	no comments		legislation at the moment
	Anti - HBs								
	HBV NAT						as verification test for		
							HBsAg positive		
	Other technique								
Hepatitis C	Anti-HCV	YES	NO	NO	all	all	no comments	NO	No plans for changes to the
	HCV NAT								legislation at the moment
	Other technique								
HTLV-1	Technique not specified							NO	No plans for changes to the
									legislation at the moment
	Anti-HTLV-1	YES	NO	NO	donors from countries	all	no comments		
					with HTLV-1 high				Tests are not mandatory, but in
					prevelence				case of a risk assessment they may
	HTLV-1 NAT								became mandatory: "Depending
	Other technique								on the data in the medical records
HTLV-2	Technique not specified						based on donor	NO	No plans for changes to the legislation at the moment
							assessment		
	Anti-HTLV-2								
	HTLV-2 NAT								
	Other technique								
Chikungunya virus	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	Anti-CHIKV								
	CHIKV NAT								
	Other technique								
Cytomegalovirus	Technique not specified	YES	NO	NO	all	all	based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	Anti-CMV								Tests are not mandatory, but in
	CMV NAT								case of a risk assessment they may
	Other technique								became mandatory: "Depending

Tested pathogen	Donor test/ technique	Legally binding	Legally binding Recommended Recommending Circumstances for application						Further comments
			on national level	authority/ association	Donor profile	Tissue/cell type	Comments	Regional differences	
Dengue Virus	Technique not specified		on national level	dationey, association	Bonor pronic	rissuc/ceii type	based on donor	NO	No plans for changes to the
Deligue virus	recillique flot specified						assessment	INO	legislation at the moment
	Anti-DENV						assessment		legislation at the moment
	NAT								
	Other technique	-							
Ebola Virus	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	NAT								
	Other technique								
Epstein-Barr virus	Technique not specified	YES	NO	NO	all	all	based on donor	NO	No plans for changes to the
•							assessment		legislation at the moment
	Anti-EBV			•	•				
	Other technique								Tests are not mandatory, but in
Hepatitis E	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	Anti-HEV								
	HEV NAT								
	Other technique								
Human Parvovirus B19	Technique not specified						based on donor	NO	No plans for changes to the
İ							assessment		legislation at the moment
	HPVB19 NAT								
	Other technique								
Herpes simplex virus	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	HSV Ag								
	HSV Ab								
	HSV NAT								
	Other technique								
West Nile Virus	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	WNV minipool NAT	_							
	WNV ID NAT	_							
	Other technique								
specify pathogen									
PARASITIC									
Babesiosis	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	Microscopy								
	Antibody detection (EIA,								
	IFA)								
	Molecular testing (NAT)								
	0.1								
	Other technique						1	110	1
Leishmaniasis	Technique not specified						based on donor	NO	No plans for changes to the
	N.A. i and a second						assessment	-	legislation at the moment
	Microscopy	-							
	Anti -Leishmania sp.								1

Tested pathogen	Donor test/ technique	Legally binding	Recommended Recommending Circumstances for application				Regional differences	Further comments	
resteu patriogen	Donor testy technique	Ecgany binding	on national level	authority/ association	Donor profile	Tissue/cell type	Comments	negional uniterences	Further comments
	Laishasania an NAT		on national level	dutilotity/ d330clation	Donor prome	rissue/ceii type	Comments		
	Leishmania sp. NAT Other technique								
Malaria	Technique not specified	YES	NO	NO	all	all	based on donor	NO	No plans for changes to the
iviaiai ia	recillique not specified	1123	NO	INO	all	all	assessment	NO	legislation at the moment
	Microscopy						assessment		legislation at the moment
	Plasmodium sp . Ab	_							Tests are not mandatory, but in
	Plasmodium sp . Ag	_							case of a risk assessment they may
	Plasmodium sp. Ag - rapid								became mandatory: "Depending
	test								on the data in the medical records
	Plasmodium sp. NAT								of the donor and the properties of
	Other technique								cells or tissues procured, additiona
Toxoplasmosis	Technique not specified	YES	NO	NO	all	all	based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	Anti- <i>Toxoplasma gondii</i>								
									Tests are not mandatory, but in
	Microscopy								case of a risk assessment they may
Tourse	Other technique	VEC	luo.	luo.	T-11	T-11	lhand on days	NO	became mandatory: "Depending
Trypanosomiasis	Technique not specified	YES	NO	NO	all	all	based on donor	NO	No plans for changes to the
	Anti- <i>Trypanosoma cruzi</i>						assessment		legislation at the moment
	Anti-rrypanosoma crazi								Tests are not mandatory, but in
	Microscopy	_							case of a risk assessment they may
	Other technique	_							became mandatory. The law says:
specify pathogen	other teaminque								
BACTERIAL									
Treponema pallidum	Technique not specified	YES	NO	N/A	N/A	all		NO	No plans for changes to the
(Syphilis)	recillique not specified	TL3	NO	IN/A	N/A	all		INO	legislation at the moment
(3) prim3)	Anti-T. pallidum	YES	NO	NO	all	all	no comments		legislation at the moment
	Microscopy	120	10	<u></u>			ino commento		
	T. pallidum NAT								
	Other technique								
Chlamydia trachomatis	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	C. trachomatis DFA								
	C. trachomatis EIA								
	C. trachomatis NAT								
	Culture								
	Other technique								
Neisseria gonorrhoeae	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	N. gonorrhoeae NAT								
	Culture								
Danie alle ale	Other technique						lhanadan 1	NO	No observation at all
Brucellosis	Technique not specified						based on donor	NO	No plans for changes to the
	Cultura						assessment	-	legislation at the moment
	Culture Other technique								
	Other technique								1

Polish Transplant Coordinating Center National Centre of Tissue and Cell Banking Department of Mother and Child, Ministry of Health

Tested pathogen	Donor test/ technique	Legally binding	Recommended	Recommending	Circumstances for a	pplication		Regional differences	Further comments
			on national level	authority/ association	Donor profile	Tissue/cell type	Comments		
Tuberculosis	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	Culture								
	Other technique								
Q-fever	Technique not specified						based on donor	NO	No plans for changes to the
							assessment		legislation at the moment
	C. burnetii Ab	_							
	C. burnetii NAT								
	Microscopy								
specify pathogen									
FUNGI									
specify pathogen									
Transmissible									
spongiform									
Other Tests									
ABO blood group	ABO typing	YES	NO	NO	all allo HSC	for HSCs	no comments	NO	
testing	Other technique								
RhD blood group	RhD typing	YES	NO	NO	all allo HSC	for HSCs	no comments	NO	No plans for changes to the legislation at the moment
testing	Other technique								
HLA testing	Technique not specified	YES	NO	NO	all allo HSC	for HSCs	no comments	NO	Plans for establishing NGS testing
									as reqiurement for potential done
	HLA Ab								screening and maching testing
	HLA Ag								Tests are not mandatory, but in
									case of a risk assessment they ma
	HLA gene								and the second s
	Other technique								became mandatory: "Depending
Genetic testing, pleas	Other technique								became mandatory: "Depending

Colour key	
	Minimum requirements as set out in Directive 2004/23/EC
	More stringent testing - legally binding on national level
	More stringent testing - recommended on national level
	Not legally binding and not recommended on national level

#### Reproductive tissues and cells

				ricpi odd	ctive tisse	ico ama e	<u> </u>		
Tested pathogen	Donor test/ technique	Legally binding	Recommended	Recommending	Circumstances for appl	cation		Regional differences	Further comments
			on national level	authority/ association	Donor profile	Tissue/cell type	Comments		
VIRAL									
HIV 1 and HIV 2	Anti-HIV 1	YES	NO	NO	all	all	no comments	NO	
	Anti-HIV 2	YES	NO	NO	all	all	no comments		
	HIV 1p24								
	HIV NAT						as verification test		
	Other technique								
Hepatitis B	HBs Ag	YES	NO	NO	all	all	no comments	NO	
	Anti-HBc	YES	NO	NO	all	all	no comments		
	Anti - HBs								
	HBV NAT						as verification test		
	Other technique								
Hepatitis C	Anti-HCV	YES	NO	NO	all	all	no comments	NO	
	HCV NAT						as verification test		
	Other technique								
HTLV-1	Technique not specified							NO	
	Anti-HTLV-1	YES	NO	NO	donors from countries with HTLV-1 high prevelence	all	no comments		
	HTLV-1 NAT		· L		prevenence		_		
	Other technique								
HTLV-2									
Chikungunya virus									
Cytomegalovirus	Technique not specified	YES	NO	NO	all	all	dependent on donor's travel and exposure history	NO	
	Anti-CMV				•		,	Ī	
	CMV NAT								
	Other technique								
Dengue Virus	·								
Ebola Virus									
Epstein-Barr virus									
Hepatitis E									
Human Parvovirus B19									
Herpes simplex virus									
West Nile Virus									
specify pathogen									
PARASITIC									
PARASITIC Leishmaniasis									

	,								
Tested pathogen	Donor test/ technique	Legally binding	Recommended	Recommending	Circumstances for appl			Regional differences	Further comments
			on national level	authority/ association	Donor profile	Tissue/cell type	Comments		
	Microscopy								
	Plasmodium sp . Ab								
	Plasmodium sp . Ag								
	Plasmodium sp. Ag - rapid								
	test								
	Plasmodium sp. NAT								
	Other technique								
Toxoplasmosis									
Trypanosomiasis									
specify pathogen									
BACTERIAL		_	_						
Treponema pallidum (Syphilis)	Technique not specified	YES	NO	N/A	non-partner donation	all	no comments	NO	
	Anti-T. pallidum								
	Microscopy								
	T. pallidum NAT								
	Other technique								
Chlamydia trachomatis	Technique not specified	YES	NO	N/A	non-partner donors	all	no comments	NO	
	C. trachomatis DFA								
	C. trachomatis EIA		1						
	C. trachomatis NAT	YES	NO	N/A	non-partner donation	all	no comments		
	Culture								
	Other technique								
Neisseria gonorrhoeae									
Brucellosis									
Tuberculosis									
Q-fever									
specify pathogen									
FUNGI									
specify pathogen									
Transmissible									
spongiform									
Other Tests									
ABO blood group testing									
RhD blood group testing	RhD typing	YES	NO	NO	all	all	no comments	NO	
	Other technique								
HLA testing									
Genetic testing, please	Specify technique	YES	NO	N/A	non-partner donors	all	genetic screening for autosomal		
specify condition							recessive genes known to be		
							prevalent, according to	1	
							international scientific evidence,	1	
							in the donor's ethnic background		
1							and an assessment of the risk of		
							transmission of inherited		
							conditions known to be present in		
I							the family must be carried out		
								1	
				l	<u> </u>	l		1	l .